Evidence map›Paper›PMID 37641137›Full record

ArticleJournal of nanobiotechnology2023

A multifunctional integrated biomimetic spore nanoplatform for successively overcoming oral biological barriers.

Qingling Song, Junfei Yang, Xiaocui Wu, Yao Li, Hongjuan Zhao, Qianhua Feng, Zhenzhong Zhang, Yun Zhang, Lei Wang

Abstract read
In one paragraph

Article in Journal of nanobiotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Qingling Song *School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, People's Republic of China.
Junfei Yang *School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, People's Republic of China.
Xiaocui WuSchool of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, People's Republic of China.
Yao LiSchool of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, People's Republic of China.
Hongjuan ZhaoSchool of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, People's Republic of China.
Qianhua FengSchool of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, People's Republic of China.
Zhenzhong ZhangSchool of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, People's Republic of China. zhangzhenzhong@zzu.edu.cn.
Yun ZhangSchool of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, People's Republic of China. zhang_yun@ymail.com.
Lei WangSchool of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, People's Republic of China. wanglei1@zzu.edu.cn.

Funding

National Natural Science Foundation of China 81972907, 82171333National Natural Science Foundation of China 82272847
6 · The paper itself

Abstract

The biological barriers have seriously restricted the efficacious responses of oral delivery system in diseases treatment. Utilizing a carrier based on the single construction means is hard to overcome these obstacles simultaneously because the complex gastrointestinal tract environment requires carrier to have different or even contradictory properties. Interestingly, spore capsid (SC) integrates many unique biological characteristics, such as high resistance, good stability etc. This fact offers a boundless source of inspiration for the construction of multi-functional oral nanoplatform based on SC without further modification. Herein, we develop a type of biomimetic spore nanoplatform (SC@DS NPs) to successively overcome oral biological barriers. Firstly, doxorubicin (DOX) and sorafenib (SOR) are self-assembled to form carrier-free nanoparticles (DS NPs). Subsequently, SC is effectively separated from probiotic spores and served as a functional vehicle for delivering DS NPs. As expect, SC@DS NPs can efficaciously pass through the rugged stomach environment after oral administration and further be transported to the intestine. Surprisingly, we find that SC@DS NPs exhibit a significant improvement in the aspects of mucus penetration and transepithelial transport, which is related to the protein species of SC. This study demonstrates that SC@DS NPs can efficiently overcome multiple biological barriers and improve the therapeutic effect.

Indexed as

BiomimeticsCapsid ProteinsAdministration, OralGastrointestinal TractSporesCapsid ProteinsBiological barrierBiomimetic sporeOral drug deliverySpore capsid

Identifiers

PMID37641137
PMCPMC10463901

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.